Pharmaceutica Analytica Acta

Instructions for Authors

Pharmaceutica Analytica Acta (PAA) provide bimonthly publication of articles in all areas related to Method validation, Chemical analysis, Drug analysis, Pharmaceutical analysis, Pharmaceutics, Spectroscopy, HPLC, Pharmaceutical formulation, Pharmaceutical technology, Validation, Chromatography, Electrophoresis on monthly basis. Pharmaceutica Analytica Acta welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately 7 days after acceptance.

The “Pharmaceutica Analytica Acta” is using Editorial Manager system for online manuscript submission, review and tracking. Editorial board members of the journal or outside experts review manuscripts; at least two independent reviewers approval followed by the editor is required for the acceptance and publication of any citable manuscript.

Submit manuscript at Online Submission System or send as an e-mail attachment to the Editorial Office at wmmsubmissions@peerreviewedjournals.com

A manuscript number will be e-mailed to the corresponding author within 72 hours.

Note: Authors are sole responsible for any scientific misconduct including plagiarism in their research articles; publisher is not responsible for any scientific misconduct happened in any published research article. As a publisher we will follow strictly scientific guidelines and EIC’s advice to retract or erratum of any article at any time if scientific misconduct or errors happened in any article.

Journal Policy Regarding the NIH Mandate

Pharmaceutica Analytica Acta will support authors by posting the published version of articles by NIH grant-holders and European or UK-based biomedical or life sciences grant holders to PubMed and PubMed Central immediately after publication

Editorial Policies and Process

Pharmaceutica Analytica Acta editorial policy that encourages researchers to submit the original research, reviews and editorial observations as articles, well supported by tables and graphic representation.

Article Processing Charges (APC)

Pharmaceutica Analytica Acta is self-financed and does not receive funding from any institution/government. Hence, the Journal operates solely through processing charges we receive from the authors and some academic/corporate sponsors. The handling fee is required to meet its maintenance. Being an Open Access Journal, Pharmaceutica Analytica Acta does not collect subscription charges from readers that enjoy free online access to the articles. Authors are hence required to pay a fair handling fee for processing their articles. However, there are no submission charges. Authors are required to make payment only after their manuscript has been accepted for publication.

Average Article prorcessing time (APT) is 55 days

The basic article processing fee or manuscript handling cost is as per the price mentioned above on the other hand it may vary based on the extensive editing, colored effects, complex equations, extra elongation of no. of pages of the article, etc.

Withdrawal Policy
Pharmaceutica Analytica Acta is organized by Walsh Medical Media, a self-supporting organization, and does not receive funding from any institution or government. Hence, the operation of the journal is solely financed by the handling fees received from authors and some academic and corporate sponsors. The handling fees are required to meet the maintenance costs of the journal. Being an open-access journal, Pharmaceutica Analytica Acta does not receive payment for subscriptions, as the articles are freely accessible over the internet. Authors of articles are required to pay a fair handling fee for processing their articles. However, there are no submission charges. Authors are required to make payment only after their manuscript has been accepted for publication. In case of withdrawal, the minimum standard article processing charge for Pharmaceutica Analytica Acta is 50% of the publication charges.

Pharmaceutica Analytica Acta is an open access journal. Each article published by the journal follows a specific format.

Fast Editorial Execution and Review Process (FEE-Review Process):

Pharmaceutica Analytica Acta journal is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.

Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.

The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.

Article Categories

• Original Articles: reports of data from original research.
• Reviews: comprehensive, authoritative descriptions of any subject within the scope of the journal. These articles are usually written by experts in the field who have been invited by the Editorial Board.
• Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association or present an important adverse reaction. Authors should clearly describe the clinical relevance or implications of the case. All case report articles should indicate that informed consent to publish the information has been granted from the patients or their guardians.
• Commentaries: short, focused, opinion articles on any subject within the scope of the journal. These articles are usually related to contemporary issues, such as recent research findings, and are often written by opinion leaders.
• Methodology articles: present a new experimental method, test or procedure. The method described may be new, or may offer a better version of an existing method.
• Letter to the Editor: these can take three forms: a substantial re-analysis of a previously published article; a substantial response to such a re-analysis from the authors of the original publication; or an article that may not cover ‘standard research’ but that may be relevant to readers.

For more information on each type of article, please contact the Editor at wmmsubmissions@peerreviewedjournals.com

Manuscript Submission

One of the authors of the article, who takes responsibility for the article during submission and peer review, should follow the instructions for submission and submit the manuscript. Please note that to facilitate rapid publication and to minimize administrative costs, Walsh Medical Media only accepts online submissions, and that there is an article-processing charge on all accepted manuscripts.

During submission, you will be asked to provide a cover letter, in which you should explain why your manuscript should be published in the journal and declare any potential competing interests. Please provide the contact details (name and email addresses) of two potential peer reviewers for your manuscript. These should be experts in their field who will be able to provide an objective assessment of the manuscript. The suggested peer reviewers should not have published with any of the authors of the manuscript within the past five years, should not be current collaborators and should not be members of the same research institution. Suggested reviewers will be considered along with potential reviewers recommended by the Editorial Board members.

A list of acceptable file formats appears below. Additional files of any type, such as movies, animations or original data files can also be submitted as part of the manuscript.

Here are the files required for submission :

• Title page
  Formats: DOC
  Must be a separate file, not embedded in the main manuscript.

• Main manuscript
  Format: DOC
  Tables less than 2 pages each (about 90 rows) should be included at the end of the manuscript.

• Figures
  Formats: JPG, JPEG, PNG, PPT, DOC, DOCX
  Figures must be sent separately, not embedded in the main manuscript.

• Cover letter
  Formats: DOC
  Must be a separate file, not embedded in the main manuscript.

The title page should:

• provide the title of the article
• list the full names, institutional addresses and email addresses for all authors
• indicate the corresponding author

Acknowledgments, Sources of Funding, and Disclosures

• Acknowledgments: The acknowledgments section lists each individual’s substantive contributions. Authors should obtain written, signed permission from all individuals listed in the ‘Acknowledgments’ section of the manuscript, because readers may infer their endorsement of data and conclusions. These permissions must be provided to the Editorial Office.
• Sources of Funding: Authors must list all sources of research support relevant to the manuscript. All grant funding agency abbreviations or acronyms should be completely spelled out.
• Conflict of Interest: Authors must state any disclosures in the cover letter when submitting a manuscript. If there is no conflict of interest, please state “Conflict of Interest: None to report.” Conflicts of interest pertain to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, membership of a board of directors, or a public association with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations. The corresponding author should collect Conflict of Interest information from all co-authors before submitting a manuscript.

Tables and Figures

Each table should be numbered and cited in sequence using Arabic numerals (i.e., Table 1, 2, 3, etc.). Titles for tables should appear above the table and be no longer than 15 words. They should be pasted at the end of the document text file, in A4 Portrait or Landscape format. These will be typeset and displayed as such in the final, published form of the article. Tables should be formatted using the ‘Table object’ in a word processing program to ensure that columns of data remain aligned when the file is sent electronically for review. Tables should not be embedded as figures or spreadsheet files. Larger datasets or tables too wide for a Landscape page can be uploaded separately, as additional files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.

Figures should be provided in a separate single .DOC, .PDF or .PPT file, with a resolution of at least 300 dpi and not be embedded in the main manuscript file. If a figure consists of separate parts, please submit a single, composite illustration page that includes all parts of the figure. There is no charge for the use of color figures. The figure legends should be included in the main manuscript text file at the end of the document, rather than as part of the figure file. For each figure, the following information should be provided: Figure numbers in sequence, using Arabic numerals, a title of 15 words maximum and a detailed legend of up to 300 words. Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder(s) to reproduce figures or tables that have previously been published elsewhere.

Supplementary Information

All Supplementary Information (figures, tables and Summary diagram/, etc.) is supplied as a single PDF file, where possible. File size within the permitted limits for Supplementary Information. Images should be a maximum size of 640 x 480 pixels (9 x 6.8 inches at 72 pixels per inch).

References

All references, including links, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, and should be formatted in the National Library of Medicine style. Each reference must have an individual reference number. Please avoid excessive referencing. Only articles, datasets and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited. The author is responsible for obtaining permission to quote personal communications and unpublished data from cited colleagues. Journal abbreviations should follow Index Medicus/MEDLINE.

Citations in the reference list should include all named authors, up to the first 6, before adding ‘et al.’. Any in press articles cited within the references and necessary for the reviewers’ assessment of the manuscript should be made available if requested by the editorial office.

Style and Language

Walsh Medical Media only accepts manuscripts written in English. Spelling should be either U.S. English or British English, but not a mixture.

Walsh Medical Media will not edit submitted manuscripts language; thus, reviewers may advise rejection of a manuscript due to grammatical errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. In-house copyediting will be minimal. Non-native speakers of English may choose to make use of our copyediting services. Please contact wmmsubmissions@peerreviewedjournals.com for more information. Abbreviations should be used as sparingly as possible and should be defined when first used.

In addition,

• Please use double-line spacing.
• Use justified margins, without hyphenating words at line breaks.
• Use hard returns only to end headings and paragraphs, not to rearrange lines.
• Capitalize only the first word and proper nouns in the title.
• Number all pages.
• Use the correct reference format.
• Format the text in a single column.
• Greek and other special characters may be included. If you are unable to reproduce a particular character, please type out the name of the symbol in full. Please ensure that all special characters are embedded in the text; otherwise, they will be lost during PDF conversion.
• SI units should be used throughout (‘liter’ and ‘molar’ are permitted).

Word count

For Original Articles, Methodology Articles and Reviews, there is no explicit limit on the length of papers submitted, but authors are encouraged to be concise. Commentaries and Case Reports should be between 800 and 1,500 words. Letters to the Editor should be between 1,000 and 3,000 words. There is also no restriction on the number of figures, tables, additional files or references that can be included. Figures and tables should be numbered in the order in which they are referenced in the text. Authors should include all relevant supporting data with each article.

The abstract of Original and Methodology Articles should not exceed 250 words and must be structured into Background, Methods, Results and Conclusions. For Reviews, please provide an unstructured, single paragraph summary of no more than 350 words, of the major points raised. For Commentaries and Case Reports, please provide a short, unstructured, single paragraph summary of no more than 150 words. For Letters to the Editor, please provide a short, unstructured, single paragraph summary of no more than 250 words.

Please minimize the use of abbreviations and do not cite references in the abstract. Please list your trial registration number after the abstract, if applicable.

Add a list of 3 to 10 keywords below the abstract.

The Accession Numbers of nucleic acid, protein sequences or atomic coordinates cited in the manuscript should be provided in square brackets and include the corresponding database name.

Initial Review Process

Submitted manuscripts will be evaluated initially by the editor-in-chief and an associate editor. A rapid, initial decision regarding whether to have a manuscript formally reviewed by two or more reviewers with appropriate expertise, or rejected without a formal review will be determined based on the quality, scientific rigor and data presentation/analysis of the manuscript. It is anticipated that approximately 70% of the submitted manuscripts will undergo formal review and 30% will be rejected without evaluation by external reviewers.

Instructions for Revised Submissions

• Please provide a copy of the revised text with changes marked in the text using either tracking changes or highlighting.
• In your written response to the reviewers’ comments, give the page number(s), paragraph(s), and/or line number(s) where each revision was made.
• Respond to each referee’s comments, indicating precisely the changes made in response to the critiques. Also, give reasons for suggested changes that were not implemented, and identify any additional changes that were made.
• Revisions not received within 2 months will be administratively withdrawn. For further consideration, the manuscript must be resubmitted de novo. At the editors’ discretion, and in cases where substantial new data are required, extensions may be granted for revisions. In such cases, every effort will be made to retain the original reviewers.

Proofs and Reprints

Electronic proofs will be sent as an e-mail attachment to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript and no changes will be made in the manuscript at the proof stage. Authors can freely download the PDF file. Hard copies of the documents are available on request. Please click on the link for the charges.

Copyright

As a member of Publisher International Linking Association, PILA, Pharmaceutica Analytica Acta follows the Creative Commons Attribution License and Scholars Open Access publishing policies.

All works published by Pharmaceutica Analytica Acta are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the work provided the original work and source is appropriately cited.